About The Drug Orphenadrine Injection aka Norflex
![ClusterMed ClusterMed](/images/clustermed.jpg)
Find Orphenadrine Injection side effects, uses, warnings, interactions and indications. Orphenadrine Injection is also known as Norflex.
Orphenadrine Injection
![Orphenadrine Injection Prescription Drug Bottle Orphenadrine Injection Prescription Drug Bottle](/images/prescriptiondrugbottle.jpg)
About Orphenadrine Injection aka Norflex |
---|
What's The Definition Of The Medical Condition Orphenadrine Injection?Clinical Pharmacology CLINICAL PHARMACOLOGY The mode of therapeutic action has not been clearly identified, but may be related to its analgesic properties.
Orphenadrine citrate does not directly relax tense muscles in man.
Orphenadrine citrate also possesses anti-cholinergic actions.
Drug Description Norflex (orphenadrine citrate) Injection DESCRIPTION Orphenadrine citrate is the citrate salt of orphenadrine (2-dimethylaminoethyl 2- methylbenzhydryl ether citrate).
It occurs as a white, crystalline powder having a bitter taste.
It is practically odorless; sparingly soluble in water, slightly soluble in alcohol.
Norflex Injection contains 60 mg of orphenadrine citrate in aqueous solution in each ampul.
Norflex (orphenadrine) Injection also contains: sodium bisulfite NF, 2.0 mg; sodium chloride USP, 5.8 mg; sodium hydroxide, to adjust pH; and water for injection USP, q.s.
to 2 mL.
Indications & Dosage INDICATIONS Orphenadrine citrate is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculo skeletal conditions.
DOSAGE AND ADMINISTRATION INJECTION: Adults - One 2 mL ampul (60 mg) intravenously or intramuscularly; may be repeated every 12 hours.
HOW SUPPLIED INJECTION: Boxes of 6 (NDC 0089-0540-06 ) 2 mL ampuls, each ampul containing 60 mg of orphenadrine citrate in aqueous solution.
Store at controlled room temperature 15°-30°C (59°-86°F).
September 2007.
Manufactured for Graceway Pharmaceuticals, LLC Bristol, TN 37620.
By Hospira, Inc.
Lake Forest, IL 60045.
Effective Date: 10/01/2007.
FDA Rev date: 2/11/2008
Medication Guide PATIENT INFORMATION No information provided.
Please refer to the WARNINGS and PRECAUTIONS sections.
Overdosage & Contraindications OVERDOSE Orphenadrine is toxic when overdosed and typically induces anticholinergic effects.
In a review of orphenadrine toxicity, the minimum lethal dose was found to be 2-3 grams for adults; however, the range of toxicity is variable and unpredictable.
Treatment for orphenadrine overdose is evacuation of stomach contents (when necessary), charcoal at repeated doses, intensive monitoring, and appropriate supportive treatment of any emergent anticholinergic effects.
CONTRAINDICATIONS Contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (megaesophagus) and myasthenia gravis.
Contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.
Side Effects & Drug Interactions SIDE EFFECTS Adverse reactions of orphenadrine are mainly due to the mild anti-cholinergic action of orphenadrine, and are usually associated with higher dosage.
Dryness of the mouth is usually the first adverse effect to appear.
When the daily dose is increased, possible adverse effects include: tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilatation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses.
Infrequently, an elderly patient may experience some degree of mental confusion.
These adverse reactions can usually be eliminated by reduction in dosage.
Very rare cases of aplastic anemia associated with the use of orphenadrine tablets have been reported.
No causal relationship has been established.
Rare instances of anaphylactic reaction have been reported associated with the intramuscular injection of Norflex (orphenadrine) Injection.
Drug Abuse And Dependence Orphenadrine has been chronically abused for its euphoric effects.
The mood elevating effects may occur at therapeutic doses of orphenadrine.
DRUG INTERACTIONS No information provided.
Warnings & Precautions WARNINGS Some patients may experience transient episodes of light-headedness, dizziness or syncope.
Norflex (orphenadrine) may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned accordingly.
Norflex (orphenadrine) Injection contains sodium bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people.
The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.
Sulfite sensitivity is seen more frequently in asthmatic than nonasthmatic people.
PRECAUTIONS Confusion, anxiety and tremors have been reported in few patients receiving propoxyphene and orphenadrine concomitantly.
As these symptoms may be simply due to an additive effect, reduction of dosage and/or discontinuation of one or both agents is recommended in such cases.
Orphenadrine citrate should be used with caution in patients with tachycardia, cardiac decompensation, coronary insufficiency, cardiac arrhythmias.
Safety of continuous long-term therapy with orphenadrine has not been established.
Therefore, if orphenadrine is prescribed for prolonged use, periodic monitoring of blood, urine and liver function values is recommended.
Pregnancy Pregnancy Category C.
Animal reproduction studies have not been conducted with Norflex (orphenadrine) .
It is also not know whether Norflex (orphenadrine) can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
Norflex (orphenadrine) should be given to a pregnant woman only if clearly needed.
Pediatric Use Safety and effectiveness in pediatric patients have not been established.
|
More Medical Conditions
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Medical Conditions Definitions Of The Day
- Aortic Coarctations ‐ Narrowing of the lumen of the aorta, caused by deformity of the…
- Gelada Baboons ‐ A genus of Old World monkeys of the subfamily CERCOPITHECINAE,…
- Detections, Signal (Psychology) ‐ Psychophysical technique that permits the estimation of the bias…
- Drug Toxicities ‐ Manifestations of the adverse effects of drugs administered therapeutically…
- Peptide Elongation Factor G ‐ Peptide Elongation Factor G catalyzes the translocation of peptidyl-tRNA…
- Systems, Vasomotor ‐ The neural systems which act on vascular smooth muscle to control…
- Platelet Activating Factor ‐ A phospholipid derivative formed by platelets, basophils, neutrophils,…
- Sialuria, Infantile Form ‐ Autosomal recessive neurodegenerative disorders caused by lysosomal…
- Spastic Paraparesis ‐ Mild or moderate loss of motor function accompanied by SPASTICITY…
- Cycles, Endometrial ‐ The period of the regularly recurring physiologic changes in…